Funded by the Stuart Scott Memorial Cancer Research Fund
Acute Myeloid Leukemia (AML) is a blood cancer that affects individuals of all ages. AML is the most common form of acute leukemia in adults. The incidence of the disease increases with age, with the majority of patients being diagnosed over the age of sixty. With aging, the disease does not respond as readily to treatments. Despite advances in the field, clinical outcomes for AML patients over the age of sixty remain poor. To improve upon current treatment options for AML patients over the age of sixty, it is essential to better understand the mechanisms that drive the disease in these patients and determine which patients benefit from current treatments. The project proposed will identify molecular features that characterize patients over the age of sixty and determine how to predict which patients benefit from current treatments and what potential mechanisms drive the disease in individuals over the age of sixty.